Small molecule · Agonist of dopamine receptor · developed by Serina Therapeutics
SER-214 is a poly(2-ethyl-oxazoline) polymer conjugate of the dopamine agonist rotigotine, designed to provide continuous drug delivery after a single weekly injection. It is studied in Parkinson's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02579473 | Phase 1 | Parkinson's Disease | Unknown | SER |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Parkinson's Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the SER page.
See SER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SER catalysts and pipeline →